Abstracts | 33 after adjusting for sex, age, age at onset of illness, numbers of previous episode, and baseline severity (baseline HAMD-17 or MWSAS), respectively. Results: Of the 131 participants, 104 (79.4%) who completed baseline measurements using WAIS-III and had at least one postbaseline assessment were included in the analysis. Subjects had low verbal IQ (VIQ) scores (88.8 ± 13.7), performance IQ (PIQ) scores (83.7 ± 14.7), and full scaled IQ (FSIQ) scores (86.4 ± 12.9) than general population norms. PIQ scores were lower than VIQ scores. Patients experiencing less digit span-forward scores were more likely to have poor treatment outcomes regardless of symptom severity measured by HAMD-17 or functioning measured by MWSAS. Conclusions: Discrepancy existing between VIQ and PIQ may be attributed to psychomotor retardation, a general slowing of mental processes recognized as a depressive symptom. MDD patients with lower scores of digital forwards were clinically useful in predicting poor outcomes after acute fluoxetine treatment.
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Abstract Objective: It is widely reported that cognitive impairment emerges in remitted depression. However, it has been suggested that the cognitive impairment may either persist due to the disorder despite effective antidepressant (ADT) treatment or emerge as a side effect of the ADT treatment itself. The aim of our study was to clarify whether anticholinergic effect influenced to the cognitive impairment in remitted depression. Methods: A total of 49 inpatients with MDD (DSM-IV) after remission (HAM-D ≤ 7) were recruited. A total of 67 healthy participants were recruited as control group. For all subjects, two cognitive tests were conducted; logical memory (LM) of the Wechsler Memory Scale Revised (WMS-R), Stroop Color and Word Test (Stroop). In addition, we collected blood samples at study entry, and measured serum anticholinergic activity (SAA) as anticholinergic effect using a radio-receptor assay technique which was developed by Tune and Coyle. We divided all MDD patients into two groups: those with positive SAA [SAA (+), n=28] and those with negative SAA [SAA (-), n=21]. Any SAA level greater than the detection of limit of a quantitative level (≥1.95 pmol / ml) is defined as SAA (+). The present study was approved by the Medical Ethics Committee of Juntendo University. All participants provided written informed consent. Results: The scores of LM of WMS-R and Stroop were significantly lower in SAA (+) than those in healthy controls (p < 0.001, Mann-Whitney U). In SAA (-) group, Scores of LM of WMS-R were significantly lower than those in healthy controls (p = 0.047, Mann-Whitney U). For Multiple regression analysis, SAA levels had a significant effect on LM of WMS-R (p = 0.005). Conclusions: Anticholinergic effect with ADT may influence to a part of cognitive impairment in remitted depression. Especially, memory impairment may be affected with the anticholinergic level.
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